Holen Sie sich die Stockscreener-App
41.76
0.36%
-0.15
Handel nachbörslich:
41.98
0.22
+0.53%
Schlusskurs vom Vortag:
$41.91
Offen:
$41.89
24-Stunden-Volumen:
1.42M
Relative Volume:
0.61
Marktkapitalisierung:
$8.61B
Einnahmen:
$2.09B
Nettoeinkommen (Verlust:
$424.88M
KGV:
20.43
EPS:
2.0439
Netto-Cashflow:
$447.20M
1W Leistung:
+4.06%
1M Leistung:
+2.86%
6M Leistung:
-12.08%
1J Leistung:
-1.32%
1-Tages-Spanne:
$41.74
$42.33
1-Wochen-Bereich:
$40.33
$42.33
52-Wochen-Spanne:
$38.80
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Compare QGEN vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
41.76 | 8.43B | 2.09B | 424.88M | 447.20M | 2.0439 |
TMO
Thermo Fisher Scientific Inc
|
527.22 | 184.37B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
198.61 | 134.19B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
584.05 | 44.72B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
120.39 | 32.52B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
330.98 | 31.41B | 3.17B | 642.63M | 516.49M | 10.77 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-13 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-22 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-06-24 | Eingeleitet | Barclays | Overweight |
| 2025-04-04 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-10-17 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-06-27 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
Barclays Downgrades Qiagen NV(QGEN.US) to Hold Rating, Cuts Target Price to $44 - Moomoo
QIAGEN NV : Barclays is less optimistic - marketscreener.com
Barclays Downgrades QIAGEN to Equalweight From Overweight, Adjusts Price Target to $44 From $48 - marketscreener.com
Qiagen N.V. stock (NL0012169213): Is sample-to-insight leadership strong enough to unlock new upside - AD HOC NEWS
Precision Trading with Qiagen N.v. (QGEN) Risk Zones - Stock Traders Daily
Qiagen N.V. stock (NL0012169213): Why does its molecular diagnostics edge matter more now for U.S. i - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Is its genomics leadership strong enough to unlock new upside? - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Does its genomics leadership deliver the biotech stability U.S. in - AD HOC NEWS
Big Money Moves: Is Qiagen NV backed by strong institutional buying2026 Price Momentum & Detailed Earnings Play Strategies - baoquankhu1.vn
Massachusetts Financial Services Co. MA Increases Stock Position in Qiagen N.V. $QGEN - MarketBeat
Trading Recap: Is Qiagen NV backed by strong institutional buyingTrade Ideas & Stepwise Trade Execution Plans - baoquankhu1.vn
Chipmakers Recap: Is Qiagen NV exposed to political risk2026 Biggest Moves & Fast Moving Stock Trade Plans - baoquankhu1.vn
Global Next-Generation Sequencing (NGS) Market to Double in Size by 2030 - GlobeNewswire Inc.
Fed Watch: Why is Qiagen NV stock going up2026 Institutional Moves & Expert Curated Trade Setup Alerts - baoquankhu1.vn
QGEN Stock Price, Quote & Chart | QIAGEN N.V. (NYSE:QGEN) - ChartMill
BlackRock Discloses Double-Digit Stake in Qiagen - TipRanks
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView — Track All Markets
Release according to Article 40, Section 1 of the WpHG - TradingView — Track All Markets
QGEN PE Ratio & Valuation, Is QGEN Overvalued - Intellectia AI
How Investors May Respond To Qiagen (QGEN) Upgrade After Reaffirmed 5% Outlook And New Product Plans - Sahm
Aug Levels: How does Qiagen NV score in quality rankingsQuarterly Risk Review & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Qiagen (QGEN) upgraded to buy by Deutsche Bank after 30% decline - MSN
Momentum Shift: Why is Qiagen NV stock going up2026 Pullback Review & Community Trade Idea Sharing Platform - baoquankhu1.vn
QGEN Technical Analysis & Stock Price Forecast - Intellectia AI
Qiagen N.V. (NYSE:QGEN) Given Average Rating of "Hold" by Brokerages - MarketBeat
Qiagen N.V. (QGEN) Rolls Out QIAstat-Dx Rise, Expands U.S. Testing Access - MSN
Qiagen N.V. (QIA.DE) stock price, news, quote and history - Yahoo Finance UK
Molecular Diagnostics Market Size is Expected to Reach USD 43.50 Billion by 2035 Owing to the Surging Demand for Accurate and Early Disease Detection Globally | SNS Insider - GlobeNewswire Inc.
Bank of America Discloses 3.01% Voting Stake in Qiagen - TipRanks
Qiagen (QGEN) Upgraded to Buy by Deutsche Bank After 30% Decline - Insider Monkey
Bruker appoints QIAGEN CEO Thierry Bernard to board of directors By Investing.com - Investing.com South Africa
Qiagen N.V. Stock: Leader in Molecular Diagnostics Faces CEO Transition Amid Steady Growth Outlook - AD HOC NEWS
Bruker appoints QIAGEN CEO Thierry Bernard to board of directors - Investing.com
Bruker brings in QIAGEN chief Thierry Bernard for board seat - Stock Titan
List of 26 Acquisitions by Qiagen (Apr 2026) - Tracxn
Bear Alert: Whats next for Qiagen NV stock2026 Weekly Recap & Risk Managed Investment Strategies - baoquankhu1.vn
Qiagen N.V. Stock: Oversold Opportunity in Sample-to-Insight Leader Amid Biotech Sector Shifts - AD HOC NEWS
Allspring Global Investments Holdings LLC Boosts Position in Qiagen N.V. $QGEN - MarketBeat
QIAGEN NV Hits New 52-Week Low at USD 38.80 Amid Declining Performance - Markets Mojo
AlphaValue/Baader Europe Upgrades Qiagen to Buy - marketscreener.com
The Bull Case For Qiagen (QGEN) Could Change Following New QuantiFERON-TB Gold Plus EvidenceLearn Why - simplywall.st
Qiagen (QGEN) Valuation Check As New QuantiFERON TB Data Reinforces Leadership In Tuberculosis Detection - Sahm
Qiagen NV at Leerink Global Healthcare Conference Transcript - GuruFocus
Qiagen (NYSE:QGEN) Cut to "Hold" at Wall Street Zen - MarketBeat
Qiagen N.V. Stock: Steady Position in Molecular Diagnostics Amid Sector Growth Opportunities - AD HOC NEWS
Qiagen (NYSE:QGEN) Sets New 52-Week LowTime to Sell? - MarketBeat
Aug Highlights: Should I set a stop loss on Qiagen NVProfit Target & High Conviction Investment Ideas - baoquankhu1.vn
Qiagen N.V. Stock: A Core Player in Molecular Diagnostics for Long-Term Investor Focus - AD HOC NEWS
QIAGEN NV Hits New 52-Week Low at USD 39.26 Amid Ongoing Decline - Markets Mojo
Qiagen N.V. stock faces pressure amid biotech sector volatility and recent market caution - AD HOC NEWS
Qiagen N.V. stock faces pressure amid biotech sector volatility and recent price dip on Frankfurt ex - AD HOC NEWS
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):